权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

GENETICALLY ENGINEERED STREPTAVIDINS

基因工程链霉亲和素

基本信息

批准号：
2649436
负责人：
TAKESHI SANO
金额：
$ 10万
依托单位：
CAPTEC, LLC
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-09-01 至 2000-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2649436
关键词：
binding proteins biotin chemical models computer simulation diagnostic tests genetic manipulation molecular biology protein engineering protein sequence protein structure recombinant proteins

项目摘要

DESCRIPTION: (adapted from applicant's abstract) The long-term goal of this project is to design and produce, by using combinations of molecular biology, computational molecular modeling, and protein biochemistry, an array of genetically engineered streptavidins with enhanced properties applicable to the development of new diagnostic and therapeutic technologies and biomedical assays. Phase I of this project will focus on molecular technologies that allow efficient, ordered immobilization of recombinant streptavidins on solid surfaces. Streptavidin, a protein which has an extremely tight binding affinity for a vitamin, biotin, is one of the most frequently used proteins in diagnostic tests and biological assays. For the last several years, the investigators at Boston University of this project have designed and produced wide variety of recombinant streptavidins that have enhanced properties over the natural protein. Phase I of this project will alter, by genetic engineering, the structures of several selected recombinant streptavidins to make them immobilizable on solid surfaces in an efficient manner. This will allow the use of the enhanced properties of these recombinant streptavidins in current solid-phase diagnostic tests and biomedical assays, with the great possibility of providing them with improved performance, greater versatility, and reduced costs. PROPOSED COMMERCIAL APPLICATION: Many currently used diagnostic and biochemical tests are solid-phase assays. In a number of solid-phase assay systems, streptavidin is often immobilized covalently on solid surfaces so that biotinylated capturing reagents, such as antibodies, and biotinylated probes, such as oligonucleotides complementary to target sequences, can be attached stably on the solid surface. Phase I of this project aims to alter, by genetic engineering, the structures of several selected recombinant streptavidins to make them immobilizable on solid surfaces in an efficient manner. The resulting streptavidin variants will be incorporated into existing solid- phase assay products to enhance their performance. They will also allow the development of new solid-phase assay products.

描述：（改编自申请人摘要）该项目是设计和生产，通过使用分子的组合，生物学、计算分子建模和蛋白质生物化学，具有增强性质的基因工程链霉亲和素阵列适用于开发新的诊断和治疗技术和生物医学分析。该项目的第一阶段将侧重于分子技术，允许有效的，有序的固定化，在固体表面上的重组链霉亲和素。链霉亲和素，一种蛋白质其对维生素生物素具有非常紧密的结合亲和力，是诊断测试中最常用的蛋白质之一，生物测定。在过去的几年里，研究人员在波士顿大学的这个项目设计和制作了各种各样的重组链霉亲和素，具有增强的性质，天然蛋白质该项目的第一阶段将改变，通过遗传工程，几种选择的重组链霉亲和素的结构以使它们以有效的方式固定在固体表面上。这将允许使用这些重组的增强的特性目前固相诊断试验和生物医学中的链霉亲和素分析，具有为它们提供改进的高性能、更高的通用性和更低的成本。拟定商业应用：许多目前使用的诊断和生化测试是固相的分析。在许多固相测定系统中，链霉抗生物素蛋白通常是共价固定在固体表面上，试剂，如抗体，和生物素化探针，如与靶序列互补的寡核苷酸可以稳定地连接在固体表面上。该项目的第一阶段旨在通过遗传改变工程，几种选择的重组链霉亲和素的结构以使它们以有效的方式固定在固体表面上。的得到的链霉亲和素变体将被结合到现有的固体中，相分析产品，以提高其性能。他们还将允许开发新的固相分析产品。